Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + cetuximab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of adebrelimab, cetuximab, and chemotherapy (either FOLFOX6 or FOLFIRI). Adebrelimab is a humanized IgG4 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), developed by Jiangsu Hengrui Pharmaceuticals. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The combination is being investigated by The First Affiliated Hospital of Zhengzhou University in a Phase 2 clinical trial for the treatment of patients with RAS/BRAF wild-type unresectable liver metastases from colorectal cancer. The rationale for this regimen is to combine immune checkpoint inhibition with EGFR-targeted therapy and cytotoxic chemotherapy to improve conversion rates to resectability and overall survival in this specific molecular subset of colorectal cancer patients.
- Brand names
- Airuika
- Other names
- adebrelimab + cetuximab + FOLFOX6adebrelimab + cetuximab + FOLFIRISHR-1316 + cetuximab + chemotherapy
02
Targets
DNATOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on adebrelimab + cetuximab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + cetuximab + chemotherapy.